Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter
1 other identifier
interventional
30
1 country
1
Brief Summary
Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE). Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 20, 2012
CompletedFirst Posted
Study publicly available on registry
June 22, 2012
CompletedJune 22, 2012
June 1, 2012
2 months
June 20, 2012
June 21, 2012
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease
You may not qualify if:
- History of previous systemic or ocular Anti-VEGF therapy
- History of previous intravitreal injection with any drug
- Intraocular pressure ≥ 22
- Glaucoma
- History or presence of thromboembolic events
- Un-controlled blood pressure
- Blood donation during the previous 3 weeks
- Relevant media opacity of the lens
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Malaya Medical Center
Kuala Lumpur, Kuala Lumpur, 59100, Malaysia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 20, 2012
First Posted
June 22, 2012
Study Start
April 1, 2012
Primary Completion
June 1, 2012
Last Updated
June 22, 2012
Record last verified: 2012-06